Recent blog posts
Medullary thyroid carcinoma Indication Strategy Report 2026: RET, Trials and Deals
Latest Hotspot
8 min read
Medullary thyroid carcinoma Indication Strategy Report 2026: RET, Trials and Deals
21 July 2026
Medullary thyroid carcinoma indication strategy report covering epidemiology, RET biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
NCT07667803 Elecoglipron Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07667803 Elecoglipron Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07667803 clinical trial report covering Elecoglipron, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600127139 L-Isoleucine/L-Leucine/L-Valine Unresectable Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600127139 L-Isoleucine/L-Leucine/L-Valine Unresectable Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
ChiCTR2600127139 clinical trial report covering L-Isoleucine/L-Leucine/L-Valine, Phase 2, endpoints, sponsor, geography, readout timing and development white
Read →
NCT07668141 Lipoic acid Nephrotoxicity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07668141 Lipoic acid Nephrotoxicity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07668141 clinical trial report covering Lipoic acid, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07669415 Tislelizumab Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07669415 Tislelizumab Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07669415 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07669740 Albumin-Bound Paclitaxel Stomach Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07669740 Albumin-Bound Paclitaxel Stomach Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07669740 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07669363 Haloperidol Cervical Intraepithelial Neoplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07669363 Haloperidol Cervical Intraepithelial Neoplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07669363 clinical trial report covering Haloperidol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07668323 Alteplase Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07668323 Alteplase Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07668323 clinical trial report covering Alteplase, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07675811 REGN-1908-1909 Cat allergy (disorder) Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07675811 REGN-1908-1909 Cat allergy (disorder) Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07675811 clinical trial report covering REGN-1908-1909, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07676331 Letrozole Hormone receptor positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07676331 Letrozole Hormone receptor positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07676331 clinical trial report covering Letrozole, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07674745 Rituximab Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07674745 Rituximab Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07674745 clinical trial report covering Rituximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20262449 Eloralintide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262449 Eloralintide Sleep Apnea, Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262449 clinical trial report covering Eloralintide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →